Frequently asked questions on medicinal products development and assessment involving companion diagnostic (CDx)
Frequently asked questions on medicinal products development and assessment involving companion diagnostic (CDx)
Frequently asked questions on medicinal products development and assessment involving companion diagnostic (CDx)
Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised
Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised
Presentation - The EU EU health policy Pharmaceutical Reform - Lilia Luchianov (DG SANTE, EC)
Guideline on specific adverse reaction follow-up questionnaires (Specific AR FUQ)
Proposed invented name(s) request form for veterinary medicinal products
Quality Review of Documents (QRD) working group plenary meeting dates
Norditropin (somatropin) supply shortage
CTIS newsflash – 24 November 2023
Agenda of the CVMP meeting 5-7 December 2023